1. Onuma Y, Wykrzykowska JJ, Garg S, et al. 5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery di sease: i nsights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials. JACC Cardiovasc Interv. 2011; 4:317–323.
2. Serruys PW, Onuma Y, Garg S, et al. 5-Year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010; 55:1093–1101.
3. Serruys PW, Ong AT, Morice MC, et al. Arterial revascularisation therapies study part ii-sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention. 2005; 1:147–156.
4. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013; 381:629–638.
5. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009; 360:961–972.
6. Park SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015; 372:1204–1212.
7. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145:247–254.
8. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005; 1:219–227.
9. Cannon CP, Battler A, Brindis RG, et al. American college of cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. a report of the american college of cardiology task force on clinical data standards (Acute coronary syndromes writing committee). J Am Coll Cardiol. 2001; 38:2114–2130.
10. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356:1020–1029.
11. Reddan DN, Szczech LA, Tuttle RH, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol. 2003; 14:2373–2380.
12. Hemmelgarn BR, Southern D, Culleton BF, et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004; 110:1890–1895.
13. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J. 2005; 149:512–519.
14. Panichi V, Migliori M, De Pietro S, et al. C reactive protein in patients with chronic renal diseases. Ren Fail. 2001; 23:551–562.
15. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002; 57:327–335.
16. Navab KD, Elboudwarej O, Gharif M, et al. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease. Curr Pharm Des. 2011; 17:17–20.
17. Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012; 380:783–785.
18. Holper EM, Blair J, Selzer F, et al. The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the national heart, lung, and blood institute percutaneous transluminal coronary angioplasty registry and dynamic registry. Am Heart J. 2006; 151:69–75.
19. Tomai F, Ribichini F, De Luca L, et al. Randomized comparison of xience v and multi-link vision coronary stents in the same multivessel patient with chronic kidney disease (Renal-Des) study. Circulation. 2014; 129:1104–1112.